This company seems to have been delisted
Reason: Acquired by AstraZeneca
Last recorded trade on: April 26, 2024
Source: https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.htmlherapy%20ambition.
Reason: Acquired by AstraZeneca
Last recorded trade on: April 26, 2024
Source: https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.htmlherapy%20ambition.
Gracell Biotechnologies
GRCL
9,44 €
Share price
0.00%
Change (1 day)
175.15%
Change (1 year)
Categories
Gracell Biotechnologies (GRCL) - Total assets
Total assets on the balance sheet as of September 2023 : €0.24 Billion
According to Gracell Biotechnologies's latest financial reports the company's total assets are €0.24 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Gracell Biotechnologies - Total assets on balance sheet (from 2019 to 2023)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2022-12-31 | €0.22 B | -21.58% |
| 2021-12-31 | €0.28 B | 137.34% |
| 2020-12-31 | €0.12 B | 128.35% |
| 2019-12-31 | €52.67 M | 179.04% |
| 2018-12-31 | €18.87 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 | €0.25 B | 3.91% | 🇺🇸 USA |